Fidaxomicin - The new drug for Clostridium difficile infection

Indian Journal of Medical Research

Volumn 142, Issue April, 2015, Pages 398-407

  Vaishnavi, Chetana ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Clinical trials; Clostridium difficile; Cost; Diarrhoea; Fidaxomicin; Hypervirulent strain; Recurrences; Vancomycin

Indexed keywords

FIDAXOMICIN; METRONIDAZOLE; VANCOMYCIN; AMINOGLYCOSIDE; ANTIINFECTIVE AGENT;

ABDOMINAL PAIN; CLINICAL TRIAL (TOPIC); CLOSTRIDIUM DIFFICILE INFECTION; COLITIS; CONJUNCTIVITIS; COST UTILITY ANALYSIS; DEATH; DEHYDRATION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DYSPHAGIA; EOSINOPHILIA; FEVER; GASTROINTESTINAL HEMORRHAGE; HEADACHE; HEALTH CARE COST; HUMAN; HYPOTENSION; MECHANISM OF ACTION; MEGACOLON; MULTICENTER STUDY (TOPIC); NAUSEA AND VOMITING; PHARYNGITIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; RESPIRATORY FAILURE; REVIEW; RNA SYNTHESIS; SEPSIS; UPPER RESPIRATORY TRACT INFECTION; WEAKNESS; CLOSTRIDIUM INFECTIONS; DRUG EFFECTS; MICROBIOLOGY; PATHOGENICITY; PEPTOCLOSTRIDIUM DIFFICILE;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; DIARRHEA; HUMANS; RECURRENCE; VANCOMYCIN;

EID: 84932090323     PISSN: 09715916     EISSN: None     Source Type: Journal    
DOI: 10.4103/0971-5916.159251     Document Type: Review

References (93)

1. Bartlett JG. Clinical practice: Antibiotic associated diarrhoea. N Engl J Med 2002; 346: 334-9.
2. Weir E, Flegel K. Protecting against Clostridium difficile illness. Can Med Assoc J 2005; 172: 1178.
3. Vaishnavi C, Singh M. Preliminary investigation of environmental prevalence of Clostridium difficile affecting inpatients in a north Indian hospital Indian J Med Microbiol 2012; 30: 89-92.
4. Riley TV. Epidemic Clostridium difficile. Med J Aust 2006; 185: 133-4.
5. Goorhuis A, Bakker D, Corver J Debast SB, Harmanus C, Notermans DW et al. Emergence of Clostridium difficile infection due to a new hypervirulent strain, polymerase chain reaction ribotype 078. Clin InfectDis 2008; 47: 1162-70.
6. Hookman P, Barkin JS. Clostridium difficile associated infection, diarrhea and colitis. World J Gastroenterol 2009; 15: 1554-80.
7. Navaneethan U, Giannella RA. Thinking beyond the colonsmall bowel involvement in Clostridium difficile infection. Gut Pathog 2009; 19: 7.
8. Libby DB, Bearman G. Bacteremia due to Clostridium difficile--review of the literature. Int J Infect Dis 2009; 13: e305-9.
9. Daruwala, C, Mercogliano G, Newman G, Ingerman MJ. Bacteremia due to Clostridium difficile: Case report and review of the literature. Clin Med Case Reports 2009; 2: 5-9.
10. Keel K, Brazier JS, Post KW, Weese S, Songer JG. Prevalence of PCR ribotypes among Clostridium difficile isolates from pigs, calves, and other species. J Clin Microbiol 2007; 45: 1963-4.
11. Hensgens MP, Goorhuis A, Notermans DW, van Benthem BH, Kuijper EJ. Decrease of hypervirulent Clostridium difficile PCR ribotype 027 in the Netherlands. Euro Surveill 2009; 14: 19402.
12. Wilcox MH, Shetty N, Fawley WN, Shemko M, Coen P. Birtles A, et al. Changing epidemiology of Clostridium difficile infection following the introduction of a national ribotyping- based surveillance scheme in England. Clin Infect Dis 2012; 55: 1056-63.
13. Stevens V, Dumyati G, Fine LS, Fisher SG, van Wijingaarden E. Cumulative antibiotic exposures over time and the risk of Clostridium difficile infection. Clin Infect Dis 2011; 53: 42-8.
14. Svenungsson B, Burman LG, Jalakas-Pornull K, Lagergren A, Struwe J, Akerlund T. Epidemiology and molecular characterization of Clostridium difficile strains from patients with diarrhea: low disease incidence and evidence of limited cross-infection in a Swedish teaching hospital. J Clin Microbiol 2003; 41: 4031-7.
15. West M, Pirenne J, Chavers B, Gillingham K, Sutherland D, Dunn D, et al. Clostridium difficile colitis after kidney and kidney-pancreas transplantation. Clin Transplant 1999; 13: 318-23.
16. Rouphael NG, O'Donnell JA, Bhatnagar J, Lewis F, Polgreen PM, Beekmann S, et al. Clostridium difficile-associated diarrhea: an emerging threat to pregnant women. Am J Obstet Gynecol. 2008; 198: 635.
17. Kim J, Smathers SA, Prasad P, Leckerman KH, Coffin S, Zaoutis T. Epidemiological features of Clostridium difficile- associated disease among inpatients at children's hospitals in the United States, 2001-2006. Pediatrics 2008; 122: 1266 70.
18. Dial S, Delaney JA, Barkun AN, Suissa S. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA 2005; 294: 2989-95.
19. Redelings MD, Sorvillo F, Mascola L. Increase in Clostridium difficile-related mortality rates: United States, 1999-2004. Emerg Infect Dis 2007; 13: 1417-9.
20. Miller BA, Chen LF, Sexton DJ, Anderson, DJ. Comparison of the burdens of hospital-onset, healthcare facility-associated Clostridium difficile infection and of healthcare associated infection due to methicillin resistant Staphylococcus aureus in community hospitals. Infect Control Hosp Epidemiol 2011; 32: 387-90.
21. Cruz, MP. Fidaxomicin (Dificid), a novel oral macrocyclic antibacterial agent for the treatment of Clostridium difficile- associated diarrhea in adults. Pharm Ther 2012; 37: 278-81.
22. Kyne L, Hamel MB, Polavaram R, Ksselly CP. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin InfectDis 2002; 34: 346-53.
23. o'Brien JA, Lahue BJ, Caro JJ, Davidson DM. The emerging infectious challenge of Clostridium difficile-associated disease in Massachusetts hospitals: clinical and economic consequences. Infect Control Hosp Epidemiol 2007; 28: 1219-27.
24. Vaishnavi C. Clostridium difficile infection: clinical spectrum and approach to management. Indian J Gastroenterol 2011; 30: 245-54.
25. Tannock GW, Munro K, Taylor C, Lawley B, Young W, Byrne B, et al. A new macrocyclic antibiotic, fidaxomicin (oPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin. Microbiology 2010; 156: 3354-9.
26. Louie TJ, Miller MA, Mullane KM, Weiss K, Lentnek A, Golan Y. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011; 364: 422-31.
27. Vaishnavi C. Clinical spectrum and pathogenesis of Clostridium difficile associated diseases. Indian J Med Res 2010; 131: 487-99.
28. Zerey M, Paton BL, Lincourt AE, Gersin KS, Kercher KW, Heniford BT. The burden of Clostridium difficile in surgical patients in the United States. Surg. Infect (Larchmt) 2007; 8: 557-66.
29. Loo VG, poirier L, Miller MA, oughton M, Libman M, Michaud S, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005; 353: 2442-9.
30. Crogan NL, Evans BC. Clostridium difficile: an emerging epidemic in nursing homes. Geriatr Nurs 2007; 28: 161-4.
31. th European Congress of Clin. Microbial & Infectious Diseases, Barcelona, Spain, Abst. 2008; p 1480.
32. Aslam S, Hamill RJ, Musher DM. Treatment of Clostridium difficile-associated disease: old therapies and new strategies. lancet Infect Dis 2005; 5: 549-57.
33. Pepin J, Saheb N, Coulombe M, Alary M, Corriveau M, Authier S, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhoea: A cohort study during an epidemic in Quebec. Clin Infect Dis 2005; 41: 254-60.
34. McDonald C, Killgore GE, Thompson A, owens RC, Khazakova Jr, Sambol SV, etal. An epidemic, toxin gene- variant strain of Clostridium difficile. N Engl J Med 2005; 353: 2433-41.
35. Kuijper EJ, Barbut F, Brazier JS, Kleinkauf N, Eckmanns T, Lambert ML, et al. Update of Clostridium difficile infection due to PCR ribotype 027 in Europe. Euro Surveill 2008; 31: 13:pii=18942.
36. Jhung MA, Thompson AD, Killgore GE, Zukowski WE, Songer G, Wary M, et al. Toxinotype V Clostridium difficile in humans and food animals. Emerg Infect Dis 2008; 14: 1039-45.
37. Gupta U, Jadav RN. Clostridium difficile in hospital patients. Indian J Med Res 1985; 82: 398-401.
38. Ayyagari A, Sharma P, Venkateswarlu, Mehta S, Agarwal KC. prevalence of Clostridium difficile in pseudomembranous and antibiotic associated colitis in North India. J Diarrhoeal Dis Res 1986; 4: 157-60.
39. Niyogi SK, Dutta P, Dutta D, Mitra U, Sikdar S. Clostridium difficile and its cytotoxin in hospitalized children with acute diarrhea. Indian Pediatr 1991; 28: 1129-32.
40. Niyogi SK, Bhattacharya SK, Dutta P, Naik TN, De SP, Sen D, et al. prevalence of Clostridium difficile in hospitalised patients with acute diarrhoea in Calcutta. J Diarrhoeal Dis Res 1991; 9: 16-9.
41. Bhattacharya MK, Niyogi SK, Rasaily R Bhattacharya SK, Dutta P Nag A, et al. Clinical manifestation of Clostridium difficile enteritis in Calcutta. J Assoc Physicians India 1991; 39: 683-4.
42. Vaishnavi C, Kochhar R, Bhasin DK, Thapa BR, Singh K. Detection of Clostridium difficile toxin by an indigenously developed latex agglutination assay. Trop Gastroenterol 1999; 20: 33-5.
43. Vaishnavi C, Kochhar R, Bhasin DK, Thapa BR, Singh K. Faecal lactoferrin latex agglutination assay for Clostridium difficile associated intestinal disease. Indian J Med Microbiol 1998; 16: 81-3.
44. Kang G, Srivastava A, Pulimood AB, Dennison D, Chandy M. Etiology of diarrhea in patients undergoing allogenic bone marrow transplantation in South India. Transplantation 2002; 73: 1247-51.
45. Vaishnavi C, Kochhar R, Bhasin, DK, Thennarasu K, Singh K. Simultaneous assay for Clostridium difficile and fecal lactoferrin in ulcerative colitis. Trop Gastroenterol 2003; 24: 13-6.
46. Kumar B, Vaishnavi C, Sandhu K, Kaur I. Clostridium difficile toxin assay in psoriatic patients. Trop Gastroenterol 2004; 25: 164-7.
47. Gogate A, De A, Nanivadekar R, Mathur M, Saraswathi K, Jog A, et al. Diagnostic role of stool culture and toxin detection in antibiotic associated diarrhoea due to Clostridium difficile in children. Indian J Med Res 2005; 122: 52-6.
48. Chaudhry R, Joshy L, Kumar L, Dhawan B. Changing pattern of Clostridium difficile associated diarrhoea in a tertiary care hospital: a 5 year retrospective study. Indian J Med Res 2008; 127: 377-82.
49. Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC. et al. Clinical practice Guidelines for Clostridium difficile Infection in Adults: 2010 Update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 2010; 31: 431-55.
50. Bauer, Martijn P, van Dissel, Jaap T, Kuijper, E.J. Clostridium difficile: controversies and approaches to management. Curr Opin Infect Dis 2009; 22: 517-24.
51. Fekety R, Mcfarland LV, Surawicz CM, Greenberg RN, Elmer GW, Mulligan, ME. Recurrent Clostridium difficile diarrhea: characterstics of and risk factors for patients enrolled in a prospective, randomized, double blinded trial. Clin Infect Dis 1997; 24: 324-33.
52. Mcfarland LV, Elimer GW, Surawucz CM. Breaking the cycle: treatment strategies fort 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol 2002; 97: 1769-75.
53. Lofmark S, Edlund C, Nord CE. Metronidazole is still the drug of choice for treatment of anaerobic infections. Clin Infect Dis 2010; 50: S16-S23.
54. Venugopal AA, Johnson S. Fidaxomicin: A novel macrocyclic antibiotic approved for treatment of Clostridium difficile infection. Clin Infect Dis 2012; 54: 568-74.
55. Crawford T, Huesgen E, Danziger L. Fidaxomicin: A novel macrocyclic antibiotic for the treatment of Clostridium difficile infection. Am J Health Syst Pharm 2012; 69: 933-43.
56. Parenti F, Pagani H, Beretta G. Lipiarmycin, a new antibiotic from Actinoplanes. I. Description of the producer strain and fermentation studies. JAntibiot 1975; 28: 247-52.
57. Coronelli C, White RJ, Lancini GC, Parenti F. Lipiarmycin, a new antibiotic from Actinoplanes. II. Isolation, chemical, biological and biochemical characterization. J Antibiot 1975; 28: 253-9.
58. Theriault RJ, Karwowski JP, Jackson M, Girolami RL, Sunga GN, Vojtko CM, et al. Tiacumicins, a novel complex of 18- membered macrolide antibiotics. I. Taxonomy, fermentation, and antibacterial activity. J Antibiot 1987; 40: 567-74.
59. Hochlowski JE, Swanson SJ, Ranfranz LM, Whittern DN, Buko AM, McAlpine JB. Tiacumicins, a novel complex of 18-membered macrolides. II. Isolation and structure determination. J Antibiot 1987; 40: 575-88.
60. Finegold SM, Molitoris D, Vaisanen ML, Song Y, Liu C, Bolarios M In vitro activities of 0PT-80 and comparator drugs against intestinal bacteria. Antimicrob Agents Chemother 2004; 48: 4898-902.
61. Ackermann G, Loffler B, Adler D, Rodloff AC. In vitro activity of 0PT-80 against Clostridium difficile. Antimicrob Agents Chemother 2004; 48: 2280-2.
62. European Medicines Agency (EMA). Committee for medicinal products for human use. London, UK: EMA; 2011. p. 1-83.
63. Gerding, DN, Muto CA, Owens RC Jr. Treatment of Clostridium difficile infection. Clin Infect Dis 2008; 46: S32-S42.
64. Shue YK, Sears PS, Shangle S, Walsh R, Lee C, Gorbach S, et al. Safety, tolerance, and pharmacokinetic studies of oPT-80 in healthy volunteers following single and multiple oral doses. Antimicrob Agents Chemother 2008; 52: 1391-5.
65. Dificid (fidaxomicin) Tablets, prescribing information. San Diego, Calif: Optimer Pharmaceuticals; May, 2011. Available from: www.dificid.com/files/prescribing.pdf, accessed on December 12, 2013.
66. Citron DM, Babakhani F, Goldstein EJ, Nagaro K, Sambol S, Sears P, et al. Typing and susceptibility of bacterial isolates from the fidaxomicin (0PT-80) phase II study for Clostridium difficile infection. Anaerobe 2009; 15: 234-6.
67. Artsimovitch I, Seddon J, Sears P. Fidaxomicin is an inhibitor of the initiation of bacterial RNA synthesis. Clin Infect Dis 2012; 55: S127-31.
68. Goldstein EJC, Citron DM, Sears P, Babakhani F, Sambol SP, Gerding DN. Comparative susceptibilities to fidaxomicin (0PT-80) of isolates collected at baseline, recurrence, and failure from patients in two phase III trials of fidaxomicin against Clostridium difficile Infection. Antimicrob Agents Chemother 2011; 55: 5194-9.
69. Goldstein EJC, Babakhani F. Citron DM. Antimicrobial activities of fidaxomicin. Clin Infect Dis 2012; 55 (Suppl 2): S143-8.
70. Louie T, Miller M, Donskey C, Mullane K, Goldstein E. Clinical outcomes, safety, and pharmacokinetics of OPT- 80 in a phase 2 trial with patients with Clostridium difficile infection. Antimicrob Agents Chemother 2009; 53: 223-8.
71. Chaparro-Rojas F, Mullane KM.Emerging therapies for Clostridium difficile infection - focus on fidaxomicin. Infect Drug Resist 2013; 6: 41-53.
72. Louie TJ, Emery J, Krulicki W, Byrne B, Mah M. 0PT-80 eliminates Clostridium difficile and is sparing of bacteroides species during treatment of C. difficile infection. Antimicrob Agents Chemother 2009; 53: 261-3.
73. Nerandzic MM, Mullane K, Miller MA, Babakhani F, Donskey CJ. Reduced acquisition and overgrowth of vancomycin- resistant enterococci and Candida species in patients treated with fidaxomicin versus vancomycin for Clostridium difficile infection. Clin Infect Dis 2012; 55 (Suppl 2): S121-6.
74. Babakhani F, Bouillaut L, Gomez A, Sears P, Nguyen L, Sonenshein AL. Fidaxomicin inhibits spore production in Clostridium difficile. Clin Infect Dis 2012; 55: S162-9.
75. Allen CA, Babakhani F, SearsP, Nguyen L, Sorg JA. Both fidaxomicin and vancomycin inhibit outgrowth of Clostridium difficile spores. Antimicrob Agents Chemother. 2013; 57: 664-7.
76. Lancaster JW. Economic impact of fidaxomicin on CDI treatment in the United States. Am J. Pharmacy 2012; 4: 114-7.
77. Smeltzer S, Hassoun A. Successful use of fidaxomicin in recurrent Clostridium difficile infection in a child. J Antimicrob Chemother 2013; 68: 1688-9.
78. Lancaster JW, Matthews SJ. Fidaxomicin: the newest addition to the armamentarium against Clostridium difficile infections. Clin Ther 2012; 34: 1-13.
79. Optimer Pharmaceuticals, Inc. Dificid (fidaxomicin) tablets prescribing information. San Diego, CA; 2011 May. Available from: www.optimerpharma.com, accessed on March 30, 2015.
80. Grant EM. Fidaxomicin: New therapy for Clostridium difficile-associated diarrhea. Formulary 2011; 46: 297-308.
81. Drekonja, DM, Butler, M, MacDonald, R, Bliss, D, Filice, GA, Rector, TS et al. Comparative effectiveness of Clostridium difficile treatments: A systematic review. Ann Intern Med 2011; 155: 839-47.
82. Cornely OA, Miller MA, Louie TJ, Crook DW, Gorbach SL. Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin. Clin Infect Dis 2012; 55: S154-61.
83. Drekonja, DM, Butler, M, MacDonald, R, Bliss, D, Filice, GA, Rector, TS et al. Comparative effectiveness of Clostridium difficile treatments: A Systematic Review Ann Intern Med 2011; 155: 839-47.
84. Cornely OA, Miller MA, Fantin B, Mullane K, Kean Y, Gorbach S. Resolution of Clostridium difficile-associated diarrhea in patients with cancer treated with fidaxomicin or vancomycin. J Clin Oncol 2013; 31: 2493-9.
85. Louie TJ, Miller MA, Crook DW, Lentnek A, Bernard L, High KP et al. Effect of age on treatment outcomes in Clostridium difficile infection. J Am Geriatr Soc 2013; 61: 222-30.
86. Clutter DS, Dubrovskaya Y, Merl MY, Teperman L, Press R, Safdar A. Fidaxomicin versus conventional antimicrobial therapy in 59 recipients of solid organ and hematopoietic stem cell transplantation with Clostridium difficile-associated diarrhea. Antimicrob Agents Chemother 2013; 57: 4501-5.
87. Hostler CJ, Chen LF. Fidaxomicin for treatment of Clostridium difficile-associated diarrhea and its potential role for prophylaxis. Expert Opin Pharmacother 2013; 14: 1529-36.
88. Crawford T, Huesgen E, Danziger L. Fidaxomicin: A novel macrocyclic antibiotic for the treatment of Clostridium difficile infection. Am J Health Syst Pharm 2012; 69: 933-43.
89. Crook DW, Walker AS, Kean Y, Weiss K, Cornely OA, Miller MA et al. Fidaxomicin versus vancomycin for Clostridium difficile infection: meta-analysis of pivotal randomized controlled trails. Clin Infect Dis 2012; 55: S93-103.
90. Ghantoji SS, Sail K, Lairson DR, Dupont HL, Garey KW. economic healthcare costs of Clostridium difficile infection: a systematic review. J Hosp Infect 2010; 74: 309-18.
91. Stranges, PM, Hutton DW, Collins CD. Cost-effectiveness analysis evaluating fidaxomicin versus oral vancomycin for the treatment of Clostridium difficile infection in the United States. Value Health 2013; 16: 297-304.
92. Bartsch SM, Umscheid CA, Fishman N, Lee BY. Is fidaxomicin worth the cost? An economic analysis. Clin Infect Dis 2013; 57: 555-61.
93. Cohen SH, Gerding DN, Johnson S, Kelley C, Loo V, McDonald L, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 2010; 31: 431-55.